Curis, Inc. (CRIS) H.C. Wainwright 27th Annual Global Investment Conference Transcript

Core Insights - Curis is focusing on emavusertib, a first-in-class IRAK4 inhibitor, which has shown promising proof-of-concept data in treating various cancers, including lymphoma, leukemia, and solid tumors [3][4]. Company Overview - Curis has a broad pipeline of novel cancer therapies, with a particular emphasis on emavusertib, which has demonstrated significant improvements over standard care in clinical studies [3]. - The leadership team at Curis is highly experienced, with each member having over 20 years of experience in drug development at notable biotech companies [5]. Clinical Data - The proof-of-concept studies for emavusertib include data from 34 patients with primary central nervous system lymphoma (PCNSL) and 21 patients with acute myeloid leukemia (AML), both showing significant efficacy [3]. - The results from the PCNSL study suggest potential effectiveness in other non-Hodgkin lymphoma (NHL) subtypes, including chronic lymphocytic leukemia (CLL) [4]. - The findings in relapsed/refractory AML indicate confidence in the drug's potential application in frontline AML treatment [4].